Drugs Made In America Acquisition LLC - 18 Feb 2025 Form 4 Insider Report for Drugs Made In America Acquisition Corp. (DMAA)

Role
10%+ Owner
Signature
Signed by managing member of Drugs Made In America Acquisition LLC /s/ Lynn Stockwell
Issuer symbol
DMAA
Transactions as of
18 Feb 2025
Net transactions value
$0
Form type
4
Filing time
18 Feb 2025, 21:55:42 UTC
Previous filing
04 Feb 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DMAA Ordinary shares Purchase +30,000 +0.72% 4,188,780 18 Feb 2025 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DMAA Rights to receive ordinary shares Purchase +30,000 +7.5% 430,000 18 Feb 2025 Ordinary shares 30,000 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects the 30,000 private units acquired by the reporting person, the Issuer's sponsor. Each private unit consists of one ordinary share and one right to receive one-eighth (1/8) of an ordinary share upon the consummation of an initial business combination. The private units were purchased at $10 per unit for an aggregate purchase price of $300,000.
F2 The rights convert automatically into ordinary shares at the completion of the Issuer's initial business combination.